Abstract
Background: Engineered adenoviruses are being increasingly explored as immunoprophylactic or immunotherapeutic vaccine vectors. Encouraging data from preclinical studies using human adenovirus vectors carrying different antigen genes have resulted in many currently ongoing clinical trials. Objective: The article seeks to review the current status of the use of adenoviruses as vaccine vectors. Methods: This review is based on the patent literature since 2000 pertaining to the development of adenovirus vaccine vectors for infectious and non-infectious diseases. Conclusion: Human adenovirus-vectored vaccines have important limitations that stem from their immunogenicity and restrict their utility. This has spurred intensive efforts to find alternative adenovirus vectors and strategies, each with its own advantages and shortcomings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
